Insmed has been granted a patent for lipo-glycopeptide cleavable derivatives to treat bacterial infections, particularly in the lungs. The compounds are designed for faster clearance and cellular uptake. The method involves administering the compound via inhalation devices like nebulizers or dry powder inhalers. GlobalData’s report on Insmed gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Insmed, Peptide pharmacophores was a key innovation area identified from patents. Insmed's grant share as of January 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of gram-positive pulmonary bacterial infections
See Also:
A recently granted patent (Publication Number: US11857597B2) discloses a method for treating Gram-positive pulmonary bacterial infections in patients. The method involves administering a composition containing a compound of Formula (II) or a pharmaceutically acceptable salt thereof via a nebulizer, dry powder inhaler (DPI), or metered dose inhaler (MDI). The patent covers various specific scenarios, including treating Gram-positive pulmonary cocci infections such as Staphylococcus, Enterococcus, and Streptococcus infections, with a particular focus on Staphyococcus aureus (S. aureus) infections, including methicillin-resistant S. aureus (MRSA) infections.
Moreover, the patent specifies that the method is particularly applicable to cystic fibrosis patients, highlighting the importance of this treatment approach for individuals with this condition. By detailing the administration methods and specific bacterial infections targeted, the patent provides a comprehensive guide for healthcare professionals looking to effectively treat Gram-positive pulmonary bacterial infections in patients, especially those with cystic fibrosis. This patent underscores the significance of personalized treatment strategies in combating respiratory infections caused by Gram-positive bacteria, offering a promising avenue for improved patient outcomes in this specific medical context.
To know more about GlobalData’s detailed insights on Insmed, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
